TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: San Diego Bleeding Esophageal Varices Study
Brief Summary: In unselected cirrhotic patients with bleeding esophageal varices to compare the influence on mortality rate, duration of life, quality of life, and economic costs of treatment of:

* Emergency portacaval shunt, and
* Emergency and long-term endoscopic sclerotherapy.


Options:
A: Arm Label: Timolol Maleate; Type: EXPERIMENTAL; Interventions: Drug: Timolol Maleate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Timolol Maleate; Assigned to Arm(s): Timolol Maleate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Endoscopic Variceal Ligation; Type: ACTIVE_COMPARATOR; Interventions: Device: multi band ligator for esophageal varices | Arm Label: Propranolol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propranolol | Intervention Type: DRUG; Name: Propranolol; Assigned to Arm(s): Propranolol | Intervention Type: DEVICE; Name: multi band ligator for esophageal varices; Assigned to Arm(s): Endoscopic Variceal Ligation
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Balloon Catheter Compared With Double Balloon Catheter for Ripening of the Unfavorable Cervix
Brief Summary: The purpose of this study is to compare between single balloon catheter and double balloon catheter for ripening the cervix among pregnant with unfavorable cervix.


Options:
A: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Foley Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Foley Catheter | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Foley Catheter | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
B: Arm Label: Cook Cervical balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: Cook cervical balloon | Arm Label: Prostin E2 Vaginal suppository; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prostin E2 Vaginal Suppository | Intervention Type: DEVICE; Name: Cook cervical balloon; Assigned to Arm(s): Cook Cervical balloon | Intervention Type: DRUG; Name: Prostin E2 Vaginal Suppository; Assigned to Arm(s): Prostin E2 Vaginal suppository
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Foley catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Atad catheter | Intervention Type: DEVICE; Name: Foley catheter; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Atad catheter; Assigned to Arm(s): 2
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: PROMS Foley and oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: PROMS no Foley bulb; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin, PROMS Foley and oxytocin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Balloon Catheter Compared With Double Balloon Catheter for Ripening of the Unfavorable Cervix
Brief Summary: The purpose of this study is to compare between single balloon catheter and double balloon catheter for ripening the cervix among pregnant with unfavorable cervix.


Options:
A: Arm Label: FOLEY BALLOON; Type: ACTIVE_COMPARATOR; Interventions: Device: FOLEY BALLOON | Arm Label: CERVIDIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: CERVIDIL (Dinoprostone) | Intervention Type: DRUG; Name: CERVIDIL (Dinoprostone); Assigned to Arm(s): CERVIDIL | Intervention Type: DEVICE; Name: FOLEY BALLOON; Assigned to Arm(s): FOLEY BALLOON
B: Intervention Type: DRUG; Name: low dose oxytocin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Foley catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Atad catheter | Intervention Type: DEVICE; Name: Foley catheter; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Atad catheter; Assigned to Arm(s): 2
D: Arm Label: Nulliparous - Foley only; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcervical Foley catheter | Arm Label: Nulliparous - Foley and oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin, Device: Transcervical Foley catheter | Arm Label: Multi(primi)parous - Foley only; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcervical Foley catheter | Arm Label: Multi(primi)parous - Foley and oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin, Device: Transcervical Foley catheter | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Multi(primi)parous - Foley and oxytocin, Nulliparous - Foley and oxytocin | Intervention Type: DEVICE; Name: Transcervical Foley catheter; Assigned to Arm(s): Multi(primi)parous - Foley and oxytocin, Multi(primi)parous - Foley only, Nulliparous - Foley and oxytocin, Nulliparous - Foley only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV for Diabetic Tractional Retinal Detachment (IBETRA Study)
Brief Summary: The purpose of this study is to compare the amount of intraoperative intraocular bleeding during 23-gauge pars plana vitrectomy (PPV) for diabetic traction retinal detachment (TRD) with and without preoperative intravitreal bevacizumab treatment.


Options:
A: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Procedure: pars plana vitrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pars plana vitrectomy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: pars plana vitrectomy; Assigned to Arm(s): A, B
C: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
D: Arm Label: Intravitreous 2 mg aflibercept injections; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2-mg Intravitreous Aflibercept Injection | Arm Label: Prompt vitrectomy plus panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Prompt Vitrectomy Plus Panretinal Photocoagulation | Intervention Type: DRUG; Name: 2-mg Intravitreous Aflibercept Injection; Assigned to Arm(s): Intravitreous 2 mg aflibercept injections | Intervention Type: PROCEDURE; Name: Prompt Vitrectomy Plus Panretinal Photocoagulation; Assigned to Arm(s): Prompt vitrectomy plus panretinal photocoagulation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV for Diabetic Tractional Retinal Detachment (IBETRA Study)
Brief Summary: The purpose of this study is to compare the amount of intraoperative intraocular bleeding during 23-gauge pars plana vitrectomy (PPV) for diabetic traction retinal detachment (TRD) with and without preoperative intravitreal bevacizumab treatment.


Options:
A: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
B: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Procedure: pars plana vitrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pars plana vitrectomy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: pars plana vitrectomy; Assigned to Arm(s): A, B
D: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Brief Summary: This study will assess the effect of pancrelipase delayed release 12,000 unit capsules on fat and nitrogen absorption in subjects 7 - 11 with pancreatic exocrine insufficiency due to Cystic Fibrosis.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pancrelipase Delayed Release | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pancrelipase Delayed Release; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): B
B: Arm Label: EUR-1008 then Kreon; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Arm Label: Kreon then EUR-1008; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Intervention Type: DRUG; Name: EUR-1008 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008 | Intervention Type: DRUG; Name: Kreon 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008
C: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Brief Summary: This study will assess the effect of pancrelipase delayed release 12,000 unit capsules on fat and nitrogen absorption in subjects 7 - 11 with pancreatic exocrine insufficiency due to Cystic Fibrosis.


Options:
A: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pancrelipase Delayed Release | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pancrelipase Delayed Release; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): B
C: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: porcine (pig) PERT; Type: ACTIVE_COMPARATOR; Interventions: Drug: porcine (pig) PERT | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: porcine (pig) PERT; Assigned to Arm(s): porcine (pig) PERT
D: Arm Label: EUR-1008 then Kreon; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Arm Label: Kreon then EUR-1008; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Intervention Type: DRUG; Name: EUR-1008 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008 | Intervention Type: DRUG; Name: Kreon 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Brief Summary: This study will assess the effect of pancrelipase delayed release 12,000 unit capsules on fat and nitrogen absorption in subjects 7 - 11 with pancreatic exocrine insufficiency due to Cystic Fibrosis.


Options:
A: Arm Label: GLP-1 Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GLP-1 | Arm Label: GIP Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GIP | Intervention Type: DRUG; Name: GLP-1; Assigned to Arm(s): GLP-1 Incretin Hormone | Intervention Type: DRUG; Name: GIP; Assigned to Arm(s): GIP Incretin Hormone
B: Arm Label: Burlulipase; Type: EXPERIMENTAL; Interventions: Drug: Burlulipase | Arm Label: Placebo (Caramel in sterile water); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Caramel in sterile water) | Intervention Type: DRUG; Name: Burlulipase; Assigned to Arm(s): Burlulipase | Intervention Type: DRUG; Name: Placebo (Caramel in sterile water); Assigned to Arm(s): Placebo (Caramel in sterile water)
C: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pancrelipase Delayed Release | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pancrelipase Delayed Release; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma
Brief Summary: Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland.

The disease develops insidiously, causing a gradual progression of symptoms; consequently most patients are diagnosed in their fourth decade of life.

Administration of somatostatin analogues such as lanreotide have been shown to result in normalisation or the decrease of GH and insulin growth factor (IGF-1) levels and improvement of clinical symptoms in acromegalic patients. The purpose of this study is to evaluate whether lanreotide is also effective on tumour volume reduction (tumour shrinkage) and the benefits of this potential tumour shrinkage on disease symptoms and patient's quality of life.


Options:
A: Arm Label: Lanreotide autogel 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide autogel 120 mg | Intervention Type: DRUG; Name: Lanreotide autogel 120 mg; Assigned to Arm(s): Lanreotide autogel 120 mg
B: Arm Label: Group 2; Type: OTHER; Interventions: Procedure: Transsphenoidal surgery | Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Preoperative lanreotide treatment | Intervention Type: DRUG; Name: Preoperative lanreotide treatment; Assigned to Arm(s): Group 1 | Intervention Type: PROCEDURE; Name: Transsphenoidal surgery; Assigned to Arm(s): Group 2
C: Arm Label: CAM2029 10 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 10 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Intervention Type: DRUG; Name: octreotide FluidCrystal® injection depot; Assigned to Arm(s): CAM2029 10 mg (Acromegaly), CAM2029 10 mg (NET), CAM2029 20 mg (Acromegaly), CAM2029 20 mg (NET)
D: Arm Label: Sandostatin s.c. (Octreotide); Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230), Octreotide (Sandostatin) | Arm Label: Pasireotide (SOM230); Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230), Octreotide (Sandostatin) | Intervention Type: DRUG; Name: Pasireotide (SOM230), Octreotide (Sandostatin); Assigned to Arm(s): Pasireotide (SOM230), Sandostatin s.c. (Octreotide)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches

Answer: A